Further to the announcement of the recommended acquisition of Quantum Pharma Plc on September 13, 2017, and the circular to Quantum shareholders dated September 29, 2017, in which it was stated that Clinigen Group plc had offered to Chris Rigg (Quantum's chief executive officer) that, upon successful completion of the recommended acquisition, he will join Clinigen's executive management team and be appointed as an executive director on the Clinigen board. The company confirm that outline terms of service have been agreed in principle with Chris Rigg in the event that the scheme of arrangement becoming effective.